CLDN1 and hepatocellular carcinoma: Interestingly, this CLDN1/Notch axis could be therapeutically targeted by CLDN1-specific monoclonal antibodies, with the latter resulting in the inhibition of Notch cleavage in HCC cell-based and CDX animal models [111].